Document Detail

Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals.
Jump to Full Text
MedLine Citation:
PMID:  25298583     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVE: The objective of this study was to evaluate the cardioprotective effect of herbal bioactive compound ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy, in experimental animals.
MATERIALS AND METHODS: Ammonium glycyrrhizinate (50, 100, 200 mg/kg, p.o.) was administered for four weeks in albino rats. Cardiomyopathy was induced with a dose of 2.5 mg/kg i.p. of doxorubicin on 1(th), 7(th), 14(th), 21(th), 28(th) day in the experimental animals. At the end of the experiment, on 29(th) day, serum and heart tissues were collected and hemodynamic, biochemical and histopathological studies were carried out.
RESULTS: Administration of doxorubicin in normal rats showed significant (P < 0.001) changes in body weight, feed intake, urine output, hemodynamic parameters like (blood pressure, heart rate, cardiac output) and in lipid profile (cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, very low density lipoprotein) indicating cardiomyopathy symptoms. Animals treated with ammonium glycyrrhizinate significantly (P < 0.05) decreased triglyceride, cholesterol, low density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels. Moreover, high density lipoprotein (HDL) levels increased in rats treated with ammonium glycyrrhizinate as compared with the normal group.
CONCLUSION: Ammonium glycyrrhizinate is effective in controlling serum lipid profile and cardiac complications in experimentally induced cardiomyopathy in animals.
Munish Garg; Tinku Singhal; Hitender Sharma
Related Documents :
7301743 - An evaluation of the nitrogen correction in the true metabolizable energy assay.
9276883 - Preservation of hatchery waste by lactic acid fermentation. 2. large-scale fermentation...
21652153 - The association between acyl-coa synthetase (acsl4) polymorphism and intramuscular fat ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Indian journal of pharmacology     Volume:  46     ISSN:  1998-3751     ISO Abbreviation:  Indian J Pharmacol     Publication Date:  2014 Sep 
Date Detail:
Created Date:  2014-10-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902477     Medline TA:  Indian J Pharmacol     Country:  India    
Other Details:
Languages:  eng     Pagination:  527-30     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Indian J Pharmacol
Journal ID (iso-abbrev): Indian J Pharmacol
Journal ID (publisher-id): IJPharm
ISSN: 0253-7613
ISSN: 1998-3751
Publisher: Medknow Publications & Media Pvt Ltd, India
Article Information
Copyright: © Indian Journal of Pharmacology
Received Day: 11 Month: 4 Year: 2014
Revision Received Day: 29 Month: 5 Year: 2014
Accepted Day: 24 Month: 7 Year: 2014
Print publication date: Season: Sep-Oct Year: 2014
Volume: 46 Issue: 5
First Page: 527 Last Page: 530
PubMed Id: 25298583
ID: 4175890
Publisher Id: IJPharm-46-527
DOI: 10.4103/0253-7613.140585

Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals
Munish Gargaff1
Tinku Singhalaff1
Hitender Sharmaaff1
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, India
Correspondence: Correspondence to: Dr. Munish Garg, E-mail:


Cardiomyopathy is a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually (but not invariably) exhibit unsuitable ventricular hypertrophy or dilatation and occurs due to varied causes that are generally genetic related. Cardiomyopathy either is confined to the heart or is part of generalized systemic disorders, which may lead to cardiovascular death or progressive heart failure-related disability.[1]

Doxorubicin, an anthracycline antibiotic, is indicated for the treatment of a wide variety of human solid tumors and leukemia patients. However, its clinical uses are limited due to high incidence of cardiotoxicity. An initial acute effect includes hypotension and transient electrocardiographic abnormalities. The chronic effects may occur several weeks or months after administration of cumulative doxorubicin.[2] Cardiomyopathy is associated with a reduction in ejection fraction thus indicating low cardiac output.[3] However, the mechanisms by which doxorubicin induces cardiac injury and dysfunction are incompletely understood. A number of doxorubicin biochemical changes have been identified that can damage cardiac reactive oxygen species (ROS),[4] production of reactive nitrogen species,[5] selective inhibition of cardiac muscle gene expression,[6] disturbance of myocardial adrenergic signaling[7] and induction of cardiac cell apoptosis.[8]

Since doxorubicin is reported to cause cardiac adverse effects by generating free radicals in cardiac cells, several natural or synthetic products with strong antioxidant potential are expected to prevent doxorubicin-induced cardimyopathy due to their free radical scavenging property. Liquorice (Glycyrrhiza glabra) is a tall shrub of the leguminosae family.[9] Pharmacological potential of G. glabra as hypoglycemic, hypocholesteremic, antiulcer, anti-inflammatory, renoprotective, and antiatherogenic have been demonstrated.[10] It is also used as a laxative, emmenagogue, contraceptive, galactagogue, antiasthmatic, antiviral agent antitussive, expectorant, anticoagulant, antiulcer, antimicrobial, antiviral, antioxidant, anti-inflammatory, antidiabetic and anticancer.[11] Since the ammonium glycyrrhizinate, which is an important constituent of G. glabra is reported to possess strong antioxidant activity,[12] it was thought worthwhile to screen this bioactive compound for its cardioprotective role in doxorubicin- induced cardiomyopathy in experimental animals.

Materials and Methods
Characterization of Ammonium Glycyrrhizinate

Ammonium glycyrrhizinate was procured from Yucca Enterprises, Mumbai and subjected for characterization to check the purity of this marker compound. The marker was thus tested for solubility, melting point, infrared (IR) and thin layer chromotography (TLC) pattern by using the standard protocol mentioned in the literature.

Experimental Animals

Swiss albino Wistar rats of either sex weighing between 100–150 g were obtained from animal house of Lala Lajpat Rai University of Veterinary and Animal Sciences (LLRUVAS), Hisar. The animals were kept in polypropylene cages (29 × 22 × 14 cm) at room temperature (25 ± 2°C) under natural dark-light cycle. Commercial pellet diet and water was provided ad libitum. The experimental protocol (Pharma Sc./485) was approved by the Institutional Animal Ethics Committee (Registration no. 134/99/CPCSEA) of Maharishi Dayanand University, Rohtak which is registered with committee for the purpose of control and supervision of experiments on animal (CPCSEA), India.

Drugs and Chemicals

Formaldehyde solution 37-41%w/v, eosin-stain solution, xylene (sulfur- free), paraffin wax 60°-62°C, hematoxylin (delafield's skin solution) was purchased from Rankam chemicals Private Limited. Glacial acetic acid, glycerin, thymol (crystals), picric acid was purchased from CDH Chemicals Private Limited. Distilled water was used for all biochemical assays. Commercially available diagnostic kits were used for the measurement of serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) content (Robonik Pritest, Mumbai, India). All other chemicals used for the biochemical parameters estimation were of analytical grade.

Experimental Design

The animals were divided into six groups consisted of six rats in each group. The groups were designed as 1 normal, 3 tests, and 2 controls. Normal group received normal saline solution (0.9% w/v NaCl). The test groups received ammonium glycyrrhizinate with doxorubicin (2.5 mg/kg). Doxorubicin dose was administered by intra-peritoneal route and ammonium glycyrrhizinate was administered orally. All the oral doses were prepared in distilled water.

  • Group 1: Normal saline (dose - 2 ml/kg)
  • Group 2: Doxorubicin (2.5 mg/kg i.p)
  • Group 3: Doxorubicin (2.5 mg/kg, i.p) + ammonium glycyrrhizinate (50 mg/kg, p.o)
  • Group 4: Doxorubicin (2.5 mg/kg, i.p.) + ammonium glycyrrhizinate (100 mg/kg, p.o)
  • Group 5: Doxorubicin (2.5 mg/kg, i.p) + ammonium glycyrrhizinate (200 mg/kg, p.o)
  • Group 6: Ammonium glycyrrhizinate (100 mg/kg, p.o).

Each group comprised of six rats and dose of doxorubicin (2.5 mg/kg) were administered on 1th, 7th, 14th, 21th and 28th day by intra-peritoneal route and 0.5 ml of volume was injected for every 100 g of rat body weight in case of doxorubicin. Doxorubicin hydrochloride (ADRIM) vial of Fresenius Oncology, Kabi, India was purchased from the local market. Ammonium glycyrrhizinate (50, 100, 200 mg/kg) was administered by oral route. The selection of dose of doxorubicin to induce cardiomyopathy and the dose of ammonium glycyrrhizinate was administered as per previously conducted studies. Toxicity study of ammonium glycyrrhizinate has already been conducted as per The Organisation for Economic Co-operation and Development (OECD) guidelines, hence were not carried out in the present study.[9]

At the end of the experimental period (i.e. on the 29th day) the rats were sacrificed for biochemical estimation. After 36 h of the last treatment, orbital blood samples were collected from all groups. Serum samples were separated for the estimation of lipid profile such as cholesterol, triglycerides, high density lipoprotein (HDL) and low density lipoprotein (LDL) The hearts were isolated for histopathological investigations. Blood pressure, heart rate and cardiac output of the experimental animals were measured by non invasive B. P. Recording instrument (AD Instruments, India).

Histopathological Studies

At the end of the experiment, heart tissues from all groups were subjected to histopathological studies. The tissue were fixed in formalin (10%), routinely processed and embedded in paraffin wax. Paraffin sections (5μm) in size were cut in glass slides, and stained with hematoxylin and eosin after de-waxing and examined under a light microscope.

Statistical Analysis

The results obtained were expressed as Mean ± SD. The statistical comparison among the groups was performed with one-way analysis of variance (ANOVA) and the significant difference between normal and experimental groups was assessed by Duncan's multiple range test (DMRT). Statistical value of P < 0.05 was considered to be significant.

Effect on Body Weight, Urine Output and Food Intake

Doxorubicin reduced the body weight, urine output and food intake in the normal group animals. However, administration of ammonium glycyrrhizinate was able to improve all the three parameters [Table 1].

Hemodynamic Studies

Doxorubicin caused significant changes in blood pressure, heart rate and cardiac output in the normal group animals. However, ammonium glycyrrhizinate was able to improve the blood pressure, heart rate and overall cardiac output [Table 2].

Serum Lipid Levels

Animals treated with doxorubicin produced a significant increase in the levels of cholesterol, triglycerides and LDL compared with the control group (P < 0.01). ammonium glycyrrhizinate (50 mg/kg) + doxorubicin, ammonium glycyrrhizinate (100, 200 mg/kg) + doxorubicin group showed a significant decrease in the level of cholesterol, triglycerides and LDL compared with the doxorubicin group, but significant increase (P < 0.01) in the level of HDL compared with the doxorubicin group [Table 3].

Histopathological Studies

Doxorubicin injected rats showed necrosis of muscle fibers, inflammatory cell infiltration and edema with fragmentation of muscle fibers as compared with the control group. Treatment with ammonium glycyrrhizinate in doxorubicin treated rats showed moderate degree of edema, necrosis and inflammatory cells compared with doxorubicin-injected rats [Figure 1].


Cardiomyopathy refers to any disease of the cardiac muscle, which ultimately affects muscle function. Heart failure is a common manifestation of most cardiomyopathy and is one of the leading causes of human morbidity and mortality worldwide.[13] Various stimuli in the heart have been recognized, including oxidative stress, serum withdrawal, angiotensin II, hyperglycemia, pressure overload, mitochondrial dysfunction and loss of cardiomyocytes survival factors.[14] Efforts continue in the field of medicines find better medicines for the treatment of cardiovascular diseases. Experimental and clinical trials are aimed at reducing the mortality rate and prevention of cardiovascular diseases. Some of the drugs actually have the potential as antioxidants, which are thought to be beneficial for cardiovascular health.[15, 16] An integrated approach is needed to manage cardiovascular diseases using the growing body of knowledge gained through scientific developments. Further, attempts were made to understand the molecular mechanism of cardio protection by the test drugs with reference to cardiovascular biomarkers, oxidative stress parameters and histopathological examination of the cardiac tissue. The present work was designed to investigate the cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals. In this study, we took model of doxorubicin-induced cardiomyopathy to assess the therapeutic potential of the test drug i.e. ammonium glycyrrhizinate. In rats, 2.5 mg/kg of doxorubicin given subcutaneously once a week for 6 weeks produced heart failure.[17] Alternatively, doxorubicin in 2.5 mg/kg i.p on every alternate day for 2 weeks led to successful induction of cardiomyopathy and failure of the heart.[18] The major limitation of clinical use is the development of cardiotoxicity. The increased serum SGOT, SGPT, cholesterol, triglyceride, LDL, VLDL levels and decreased levels of HDL due to several mechanisms for doxorubicin-induced cardiomyopathy, which include inhibition of nucleic acid,[19] release of vasoactive amines,[20] alterations in membrane-bound enzymes,[21] abnormalities in mitochondria[22] and an imbalance of myocardial electrolytes[23] were noticed. Treatment with doxorubicin increased serum marker of SGOT and SGPT. The pre-treatment with attenuated this increase in SGOT and SGPT level. Serum level of SGOT and SGPT were significantly decreased by treatment with ammonium glycyrrhizinate solution. The increased levels of serum enzymes in myocardial toxicity may be due to the leakage of the enzymes into the blood.[24] Light micrograph of doxorubicin-injected rats showed necrosis of muscle fibers, inflammatory cell infiltration and edema with fragmentation of muscle fibers as compared with the control group. Treatment with ammonium glycyrrhizinate in doxorubicin-treated rats (ammonium glycyrrhizinate + doxorubicin) showed moderate degree of edema, necrosis and inflammatory cells compared with doxorubicin-injected rats. To conclude, the present result suggests that ammonium glycyrrhizinate prevented the doxorubicin-induced cardio-toxicity by boosting the endogenous antioxidant activity. It could be due to the antioxidant activity and restoration of myocardial biomarkers of lipid profile. Further studies are needed to understand the mechanism of action of ammonium glycyrrhizinate.


Source of Support: Nil

Conflict of Interest: No


Financial support from University Grants Commission under Special Assistance Program (SAP) at DRS level sanctioned to the department is highly acknowledged.

1. Maron BJ,Towbin JA,Thiene G,Antzelevitch C,Corrado D,Arnett D,et al. American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classifications of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and PreventionCirculationYear: 200611318071616567565
2. El-Sayed M,El-azeem A,Afify A,Shabane H,Ahmed H. Cardioprotective effects of Curcuma longa L. extracts against doxorubicin-induced cardiotoxicity in ratsJ Med Plants ResYear: 201117404958
3. Balakumar P,Singh P,Singh M. Rodent models of heart failureJ Pharmacol Toxicol MethodsYear: 20075611017391988
4. Santos RV,Batista ML,Caperuto EC,Costa Rosa LF. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in ratsClin Exp PharmacolYear: 20073412949
5. Pacher P,Liqudet L,Bai P,Mabley JG,Kaminski PM,Virag L,et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin induced cardiac dysfunctionCirculationYear: 200310789690412591762
6. Ito H,Torii M,Suzuki T. Decreased superoxide dismutase activity and increased superoxide anion production in cardiac hypertrophy of spontaneously hypertensive ratsClin Exp HypertensionYear: 19951780316
7. Yoshikawa T,Handa S,Suzuki M,Nagami K. Abnormalities in sympathoneuronal regulation are localized to failing myocardium in rabbit heartJ Am Coll CardiolYear: 19942421058006268
8. Dowd NP,Scully M,Adderley SR,Cunningham AJ,Fitzgerald DJ. Inhibition of cyclo-oxygenase-2 aggrevates doxorubicin mediated cardiac injury in vivoJ Clin InvestYear: 20011085859011518732
9. Isbrucker RA,Burdock GA. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizinRegul Toxicol PharmacolYear: 2006461679216884839
10. Ojha S,Golechha M,Kumari S,Bhatia J,Arya DS. Glycyrrhiza glabra protects from myocardial ischemia-reperfusion injury by improving hemodynamic, biochemical, histopathological and ventricular functionExp Toxicol PatholYear: 2013652192721975080
11. Harwansh RK,Patra1 KC,Pareta1 SK,Singh J,Biswas R. Pharmacological studies of Glycyrrhiza glabra- a reviewPharmacologyonlineYear: 2011210328
12. Imai K,Takagi Y,Iwazaki A,Nakanishi K. Radical scavenging ability of glycyrrhizinFree Radic AntioxidYear: 20133402
13. Sheikh F,Chen JU. Mouse models for cardiomyopathy researchProg Pediatr CardiolYear: 2007242734
14. MacLellan WR,Schneider MD. Death by design. Programmed cell death in cardiovascular biology and diseaseCirc ResYear: 199781137449242174
15. Kushi LH,Folsom AR,Prineas RJ,Mink PJ,Wu Y,Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal womenN Engl J MedYear: 19963341156628602181
16. Miller LG. Herbal medicinal: Selected clinical considerations focusing on known or potential drug-herb interactionsArch Intern MedYear: 19981582200119818800
17. Scenczi O,Kemecsei P,Hollthuijsen MF,Van Riel NA,Vander GJ,Pacher P,et al. Poly (ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failureBiochem PharmacolYear: 2005697253215710350
18. Lou H,Danelisen I,Singal PK. Cytokines are not upregulated in doxorubicin-induced cardiomyopathy and heart failureJ Mol Cell CardiolYear: 2004366839015135663
19. Arena E,Bionda F,D’Alessndro N,Dusoncher L,Gebbia N,Gerbasi R. DNA, RNA protein synthesis in heart, liver and brain of mice treated with denaturation of adriamyinInt Res Commun Syst Med SciYear: 19842105431061
20. Bristow MR,Mason JW,Billingham ME,Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathyAm Heart JYear: 1981102709187282516
21. Singal PK,Panagia V. Direct effect of Adriamycin on the rat heart sarcoplasmaRes Commun Chem Pathol PharmacolYear: 19844367776142511
22. Singal PK,Segstro RJ,Singh RP,Kutryk MJ. Changes in lysosomal morphology and enzyme activities during the development of adriamycin induced cardiomyopathyCan J CardiolYear: 19851139473931886
23. Oslan HM,Younh DM,Prieur DJ,LeRoy AF,Reagan RL. Electrolyte and oxidation products of certain lipidsJ Biol ChemYear: 197417425764
24. Bruce JIe. Plasma membrane calcium pump regulation by metabolic stressWorld J Biol ChemYear: 20101221821537477


[Figure ID: F1]
Figure 1 

Effect of ammonium glycyrrhizinate for 29 days on histopathological alteration in normal and doxorubicin injected rats (a) Control rats (b) heart tissue administered with ammonium glycyrrhizinate (50 mg/kg) + doxorubicin showing mild focal vacoulation and loss of striations (c) heart tissue administered with ammonium glycyrrhizinate (100 mg/kg) + doxorubicin showing mild vascular congestion and hemorrhage and heat muscle show vacuolation with loss of cross striations with increased cyoplasmic eosinophilia (d) Doxorubicin induced and treated with ammonium glycyrrhizinate solution (200 mg/kg) showed focal hemorrhages and less loss of striations (e) Doxorubicin induced Cardiotoxicity heart showed more number of inflammatory cell, hemorrhage, edema and necrosis in cardiac cell (f) Ammonium glycyrrhizinate solution (100 mg/kg) showing no vacoulation, hemorrhages and loss of striations

[TableWrap ID: T1] Table 1 

Effect of ammonium glycyrrhizinate on body weight, food intake and urine output in doxorubicin-induced cardiotoxicity in rats (n=6)

[TableWrap ID: T2] Table 2 

Effect of ammonium glycyrrhizinate on blood pressure, heart rate and cardiac output in doxorubicin-induced cardiotoxicity in rats

[TableWrap ID: T3] Table 3 

Effect of ammonium glycyrrhizinate on cardiac functions in doxorubicin-induced cardiotoxicity in rats

Article Categories:
  • Research Article

Keywords: KEY WORDS Ammonium glycyrrhizinate, cardiac failure, cardiomyopathy, doxorubicin.

Previous Document:  Novel 2,5-disubstituted-1,3,4-oxadiazoles as anti-inflammatory drugs.
Next Document:  Chemopreventive potential of Apium leptophyllum (Pers.) against DMBA induced skin carcinogenesis mod...